Company
Every investor coverage indicates participated in a round Arana Therapeutics Limited raised.
Companies Arana Therapeutics Limited acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr George Jessup | Director (former) | GBS Ventures (Tue 10 Mar 2009), GBS Ventures (Fri 27 Feb 2009) |
Stories naming Arana Therapeutics Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures' letter to Arana Therapeutics shareholders covers Cephalon's proposed cash takeover, an attached dividend, the board's recommendation to accept, and Cephalon's pre-bid purchase of a 19.8% stake.
Cephalon has announced plans to buy out Arana Therapeutics shareholders at $1.40 a share, potentially $1.45, valuing the ASX-listed target around $318 million; its independent directors back the bid unless a better one emerges.